Cat No.
CEI-0046
Description
Crizotinib (PF-02341066) can inhibit c-Met and ALK with IC50 of 11 nM and 24 nM.
CAS No.
877399-52-5
Targets
ALK, c-Met
Chemical Name
3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
M.Wt
450.34
Purity
>99%
Solubility
DMSO 20 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
As an ATP-competitive, small-molecule inhibitor, crizotinib (PF-02341066), c-Met (also known as hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK).Crizotinib inhibited the growth and survival of cell lines dependent upon c-Met or ALK enzymatic activity.Crizotinib has been particularly effective against anaplastic large cell lymphoma and non-small cell lung cancer (NSCLC) cell lines, and that NSCLC cell lines harbors ALK translocations which would lead to expression of oncogenic ALK fusion proteins.
